Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in japan

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 6, 2011, Pages 1375-1384

  Goto, Shunsuke ^a   Komaba, Hirotaka ^a,b   Moriwaki, Kensuke ^a,c   Fujimori, Akira ^d   Shibuya, Koji ^e   Nishioka, Masato ^f   Kim, Jong Il ^g   Yoshiya, Kunihiko ^h   Shin, Jeongsoo ⁱ   Hasegawa, Hirohito ^j   Taniguchi, Masatomo ^k   Fujii, Hideki ^a   Nishi, Shinichi ^a   Kamae, Isao ^a,l   Fukagawa, Masafumi ^a,b  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c International University of Health and Welfare   (Japan)

^d Konan Hospital   (Japan)

^e Kobe Rosai Hospital   (Japan)

^f Sumiyoshigawa Clinic   (Japan)

^g Chibune General Hospital   (Japan)

^h Hara Genitourinary Hospital   (Japan)

ⁱ Motomachi HD Clinic   (Japan)

^j Konan Hospital Foundation Rokko Island Hospital   (Japan)

^k KYUSHU UNIVERSITY   (Japan)

^l KEIO UNIVERSITY   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CALCIUM LACTATE; CINACALCET; FALECALCITRIOL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PHOSPHORUS; SEVELAMER;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIALYSATE LEVEL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; FRACTURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; JAPAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OPEN STUDY; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; QUALITY ADJUSTED LIFE YEAR; RISK REDUCTION; SENSITIVITY ANALYSIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHELATING AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; HYPERPHOSPHATEMIA; JAPAN; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MIDDLE AGED; MODELS, ECONOMIC; PHOSPHORUS; QUALITY-ADJUSTED LIFE YEARS; RENAL DIALYSIS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79958201887     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.08841010     Document Type: Article

References (56)

1. U.S. Renal Data System: USRDS 2009 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, 2009
2. Fukuhara S, Yamazaki C, Hayashino Y, Higashi T, Eichleay MA, Akiba T, Akizawa T, Saito A, Port FK, Kurokawa K: The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ 7: 217-231, 2007
3. Komaba H, Moriwaki K, Kamae I, Fukagawa M: Towards cost-effective strategies for treatment of chronic kidney disease- mineral and bone disorder in Japan. Ther Apher Dial 13[Suppl 1]: S28-S35, 2009
4. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15: 2208-2218, 2004
5. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK: Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 67: 1179-1187, 2005
6. Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, Itami N, Ogata S, Kimata N, Shinoda T, Syouji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Fujii N, Marubayashi S, Morita O, Wakai K, Wada A, Iseki K, Tsubakihara Y: An overview of regular dialysis treatment in Japan (as of 31 December 2007). Ther Apher Dial 13: 457-504, 2009
7. Hutchison AJ: Oral phosphate binders. Kidney Int 75: 906-914, 2009
8. Tonelli M, Pannu N, Manns B: Oral phosphate binders in patients with kidney failure. N Engl J Med 362: 1312-1324, 2010
9. Goto S, Komaba H, Moriwaki K, Kamae I, Fukagawa M: The cost-effectiveness for first-line lanthanum carbonate therapy of Japanese dialysis patients with hyperphosphatemia [Abstract]. J Am Soc Nephrol 20: 538A, 2009
10. Brennan A, Akehurst R, Davis S, Sakai H, Abbott V: The costeffectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 10: 32-41, 2007
11. Guideline working group, Japanese Society for Dialysis Therapy: Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Aphr Dial 12: 511-522, 2008
12. Payne RB, Little AJ, Williams RB, Milner JR: Interpretation of serum calcium levels in patients with abnormal serum proteins. BMJ 4: 643-646, 1973
13. Drummond MF, McGuire A: Economic Evaluation in Health Care: Merging Theory With Practice, New York, Oxford University Press, 2001
14. Nakai S, Akiba T, Kazama J, Yokoyama K, Fukagawa M, Tominaga Y, Iseki K, Tsubakihara Y: Patient Registration Committee of the Japanese Society for Dialysis Therapy, Tokyo, Japan: Effects of serum calcium, phosphorous, and intact parathyroid hormone levels on survival in chronic hemodialysis patients in Japan. Ther Apher Dial 12: 49-54, 2008
15. Yamada S, Taniguchi M, Fujisaki K, Tsuruya K, Hirakata H, Iida M: Incidence and risk factors for bone fractures among hemodialysis patients in the Q-Cohort Study: A prospective multicenter cohort study in Japan [Abstract]. J Jpn Soc Dial Ther 41[Suppl 1]: S597, 2008 (in Japanese)
16. Taniguchi M, Yamada S, Tsuruya K, Iida M, Hirakata H: Associatio between cardiovascular events and bone fractures among hemodialysis patients in the Q-Cohort Study: A prospective multicenter cohort study in Japan [Abstract]. Kidney Metab Bone Dis 21: 352, 2008 (in Japanese).
17. Kimata N, Albert JM, Akiba T, Yamazaki S, Kawaguchi T, Fukuhara S, Akizawa T, Saito A, Asano Y, Kurokawa K, Pisoni RL, Port FK: Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: The Japan dialysis outcomes and practice patterns study. Hemodial Int 11: 340-348, 2007
18. Nakai S, Shinzato T, Sanaka T, Kikuchi K, Kitaoka T, Shinoda T, Yamazaki C, Sakai R, Omori H, Morita O, Iseki K, Kubo K, Tabei K, Masakane I, Fushimi K, Wada A, Miwa N, Akiba T: The current state of chronic dialysis treatment in Japan. J Jpn Soc Dial Ther 35: 1155-1184, 2002
19. Jadoul M, Albert JM, Akiba T, Akizawa T, Arab L, Bragg-Gresham JL, Mason N, Prutz KG, Young EW, Pisoni RL: Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 70: 1358-1366, 2006
20. Stehman-Breen CO, Sherrard DJ, Alem AM, Gillen DL, Heckbert SR, Wong CS, Ball A, Weiss NS: Risk factors for hip fracture among patients with end-stage renal disease. Kidney Int 58: 2200-2205, 2000
21. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM: PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47: 149-156, 2006
22. Jihou: National Health Insurance Price List, Tokyo, Jihou Press, 2010 (in Japanese)
23. Saito I, Kobayashi M, Matsushita Y, Mori A, Kawasugi K, Saruta T: Cost-utility analysis of antihypertensive combination therapy in Japan by a Monte Carlo simulation model. Hypertens Res 31: 1373-1383, 2008
24. Kondo A, Zierler BK, Isokawa Y, Hagino H, Ito Y: Comparison of outcomes and costs after hip fracture surgery in three hospitals that have different care systems in Japan. Health Policy 91: 204-210, 2009
25. Sugisaki H, Ohta Y, Ohira S, Onoyama O, Kuma H, Suzuki M, Yamakawa T, Yoshida T, Suzuki M, Ono T, Tozawa S, Miyamoto T, Yamazaki C: Cost of dialysis treatment in Japan: Eleventh annual report of the Japanese Association of Dialysis Physicians, 2007. J Jpn Ass Dial Physicians 23: 49-94, 2008 (in Japanese)
26. Fukuhara S, Lopes AA, Bragg-Gresham JL, Kurokawa K, Mapes DL, Akizawa T, Bommer J, Canaud BJ, Port FK, Held PJ: Worldwide Dialysis Outcomes and Practice Patterns Study: Health-related quality of life among dialysis patients on three continents: The Dialysis Outcomes and Practice Patterns Study. Kidney Int 64: 1903-1910, 2003
27. Inada O, Nishimura S, Matsushima M, Seino Y, Tsuda K: The direct medical costs and the quality of life in patients with artificial dialysis and type 2 diabetes. J Jpn Diab Soc 50: 1-8, 2007 (in Japanese)
28. Ara R, Brazier J: Predicting the short form-6D preferencebased index using the eight mean short form-36 health dimension scores: Estimating preference-based health-related utilities when patient level data are not available. Value Health 12: 346-353, 2009
29. Mahoney EM, Jurkovitz CT, Chu H, Becker ER, Culler S, Kosinski AS, Robertson DH, Alexander C, Nag S, Cook JR, Demopoulos LA, DiBattiste PM, Cannon CP, Weintraub WS: TACTICS-TIMI 18 Investigators: Treat angina with aggrastat and determine cost of therapy with an invasive or conservative strategy-thrombolysis in myocardial infarction. Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction. JAMA 16: 1851-1858, 2002
30. Pickard AS, Johnson JA, Feeny DH: Responsiveness of generic health-related quality of life measures in stroke. Qual Life Res 14: 207-219, 2005
31. Hisashige T, Katayama T, Ishibashi T, Imai M, Iwamoto Y, Ohishi M, Ohsawa I, Kawaguchi T, Kishikami H, Yoshikawa R, Kobayashi T, Bando H, Hotta N: Estimation of the quality of the life in patients with diabetes. In: Economic Estimationof Healthcare Service by Disease Management, Report on Research on Health Services 2000, edited by Hisashige T, Tokyo, Ministry of Health, Labour and Welfare of Japan, 2000, pp 91-98 (in Japanese)
32. Hagino H, Nakamura T, Fujiwara S, Oeki M, Okano T, Teshima R: Sequential change in quality of life for patients with incident clinical fractures: A prospective study. Osteoporos Int 20: 695-702, 2009
33. Huybrechts KF, Caro JJ, Wilson DA, O'Brien JA: Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 8: 549- 561, 2005
34. Chertow GM, Burke SK, Raggi P: Treat to Goal Working Group: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 62: 245-252, 2002
35. Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M: Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867-2878, 2007
36. St Peter WL, Fan Q, Weinhandl E, Liu J: Economic evaluation of sevelamer versus calcium-based phosphate binders in hemodialysis patients: a secondary analysis using centers for Medicare & Medicaid services data. Clin J Am Soc Nephrol 4: 1954-1961, 2009
37. Suki WN, Zabaneh R, Cangiano JL, Reed J, Fischer D, Garrett L, Ling BN, Chasan-Taber S, Dillon MA, Blair AT, Burke SK: Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130- 1137, 2007
38. St Peter WL, Liu J, Weinhandl E, Fan Q: A comparison of sevelamer and calcium-based phosphate binders on mortality, hospitalization, and morbidity in hemodialysis: A secondary analysis of the Dialysis Clinical Outcomes Revisited (DCOR) randomized trial using claims data. Am J Kidney Dis 51: 445-454, 2008
39. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607-617, 1998
40. Tentori F, Blayney MJ, Albert JM, Gillespie BW, Kerr PG, Bommer J, Young EW, Akizawa T, Akiba T, Pisoni RL, Robinson BM, Port FK: Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52: 519-530, 2008
41. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT: Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group: The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis 46: 925-932, 2005
42. Isakova T, Gutie ́rrez OM, Chang Y, Shah A, Tamez H, Smith K, Thadhani R, Wolf M: Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 20: 388-396, 2009
43. Kovesdy CP, Kuchmak O, Lu JL, Kalantar-Zadeh K: Outcomes associated with phosphorus binders in men with non-dialysisdependent CKD. Am J Kidney Dis 56: 842-851, 2010
44. Hutchison AJ, Barnett ME, Krause R, Kwan JT, Siami GA: SPD405-309 Lanthanum Study Group: Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment. Nephron Clin Pract 110: c15-c23, 2008
45. Goodkin DA, Bragg-Gresham JL, Koenig KG, Wolfe RA, Akiba T, Andreucci VE, Saito A, Rayner HC, Kurokawa K, Port FK, Held PJ, Young EW: Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: The Dialysis Outcomes and Practice Patterns Study (DOPPS). J Am Soc Nephrol 14: 3270-3277, 2003
46. Finn WF, Joy MS, Hladik G: Lanthanum Study Group: Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 62: 193-201, 2004
47. Joy MS, Finn WF: LAM-302 Study Group: Randomized, double- blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am J Kidney Dis 42: 96-107, 2003
48. Shigematsu T: Lanthanum Carbonate Research Group: Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis. Ther Apher Dial 12: 55-61, 2008
49. Iwasaki Y, Takami H, Tani M, Yamaguchi Y, Goto H, Goto Y, Goto Y, Shigematsu T: Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients. Ther Apher Dial 9: 347-351, 2005
50. Côté C: Red Book Pharmacy's Fundamental Reference 2008 edition, Montvale, NJ, PDR Network, 2008
51. Côté C: Red Book Pharmacy's Fundamental Reference 2009 edition, Montvale, NJ, PDR Network, 2009
52. Côté C: Red Book Pharmacy's Fundamental Reference 2010 edition, Montvale, NJ, PDR Network, 2010
53. Tonelli M, Winkelmayer WC, Jindal KK, Owen WF, Manns BJ: The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 64: 295-304, 2003
54. Ito K, Elkin EB, Girotra M, Morris MJ: Cost-effectiveness of fracture prevention in men who receive androgen deprivation therapy for localized prostate cancer. Ann Intern Med 152: 621-6219, 2010
55. Sanders GD, Bayoumi AM, Holodniy M, Owens DK: Costeffectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med 148: 889-903, 2008
56. Manns B, Meltzer D, Taub K, Donaldson C: Illustrating the impact of including future costs in economic evaluations: An application to end-stage renal disease care. Health Econ 12: 949-958, 2003